Moderna Vaccine Shows Phase 3 Benefit
Moderna and Merck’s phase 3 trial found 42% lower melanoma recurrence or death risk over two years.
October 23, 2026 · Updated Oct 23, 6:20am ET
TIME MagazineA Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42%
ABC NewsmRNA cancer vaccine helps reduce chances of melanoma patients' tumors returning
New York PostFirst-of-its-kind cancer vaccine helps reduce chances of melanoma patients’ tumors returning: study
The New York TimesMelanoma Vaccine Ushers in New Hope for Cancer Patients
BBC NewsFirst personalised cancer vaccine cuts risk of disease returning in major trial
Just the NewsModerna stock plummets after reported leak of disappointing cancer-vaccine data
The Guardian‘Bespoke’ mRNA vaccine significantly reduces risk of melanoma recurrence or death, clinical trial shows
Daily MailWorld-first cancer vaccine trial slashes death in research by Aussie
Scientific AmericanHere’s what Moderna’s latest mRNA cancer vaccine data actually show
Joe.My.God.WaPo: Melanoma Vaccine Trial Shows Great Promise
50%
Left · 5
20%
Center · 2
30%
Right · 3
Pano rates the coverage Balanced.
What happened
Moderna and Merck said their personalized mRNA vaccine intismeran, added to Keytruda, cut the two-year risk of melanoma recurrence or death by 42% versus Keytruda alone. The companies released the phase 3 results early after leaked data surfaced before a planned cancer meeting presentation in Madrid. The trial enrolled 1,137 patients with high-risk melanoma whose tumors had been removed by surgery. Intismeran uses mutations from each patient’s tumor to train immune cells to recognize cancer if it returns, while Keytruda helps the immune system attack cancer. Trial investigator Georgina Long
Georgina V. LongAustralian melanoma oncologist and researcher called it a new post-surgery treatment approach. Overall-survival data remain unavailable.
How the left told it
Left-leaning outlets framed the results as a hopeful cancer-vaccine milestone, while stressing the science is still moving toward harder proof. The New York Times linked the findings to broader momentum in cancer vaccines and noted the companies have not shown longer survival. TIME focused on intismeran as a new way to train immunity against each patient’s tumor.
How the right told it
Right-leaning outlets cast the trial as a landmark advance, with more attention to national scientific pride and market backlash. The New York Post cited outside experts saying the success strengthens the wider cancer-vaccine field. Daily Mail highlighted a Sydney scientist leading a world-first trial. Just the News centered the stock plunge after leaked data disappointed investors.
Moderna Merck Melanoma Vaccine Trial
Part of the storyline · Storyline →- Oct 23Moderna Vaccine Shows Phase 3 Benefit (this story)Balanced
- Oct 22Moderna-Merck Vaccine Cuts Melanoma RecurrenceBalanced
